Acute Heart Failure (AHF) Pipeline Summary

DelveInsight’s, “Acute Heart Failure (AHF) - Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acute Heart Failure (AHF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Heart Failure (AHF): Understanding

Acute Heart Failure (AHF): Overview

Acute heart failure (AHF) is a clinical syndrome characterized by the rapid onset or worsening of signs and symptoms of heart failure that requires urgent medical evaluation and treatment. It may present as de novo heart failure in patients without a previous history of HF or as acute decompensated heart failure (ADHF) in individuals with chronic HF. AHF is primarily associated with systemic and pulmonary congestion resulting from elevated cardiac filling pressures and may lead to impaired organ perfusion if left untreated. Despite advances in chronic heart failure management, AHF remains a major cause of hospitalization, with high rates of mortality and readmission.

AHF develops in the presence of an underlying structural or functional cardiac abnormality and is often precipitated by acute events. Common causes include acute coronary syndrome or myocardial infarction, worsening chronic heart failure, uncontrolled hypertension, cardiac arrhythmias (particularly atrial fibrillation), valvular heart disease, myocarditis, and cardiomyopathies. Non-cardiac precipitating factors such as respiratory infections, pulmonary embolism, renal dysfunction, anemia, medication non-adherence, excessive salt or fluid intake, and adverse drug effects can also trigger acute decompensation by increasing cardiac workload or promoting fluid retention.

The pathophysiology of AHF is heterogeneous and depends on the underlying cardiac disorder and precipitating factors. Acute impairment of systolic and/or diastolic ventricular function leads to increased ventricular filling pressures, elevated preload and afterload, and reduced cardiac output. Neurohormonal activation involving the sympathetic nervous system and the renin–angiotensin–aldosterone system initially compensates for reduced perfusion but eventually becomes maladaptive, promoting vasoconstriction, sodium and water retention, and ventricular remodeling.

The diagnosis of AHF is based on a combination of clinical assessment, laboratory investigations, and imaging studies. Patients typically present with acute dyspnea, orthopnea, pulmonary crackles, peripheral edema, elevated jugular venous pressure, and signs of congestion or hypoperfusion. Diagnostic evaluation includes electrocardiography, chest radiography, echocardiography, and measurement of natriuretic peptides (BNP or NT-proBNP) to support the diagnosis of heart failure. Cardiac troponins, renal and liver function tests, and assessment of oxygen saturation help identify precipitating factors, evaluate end-organ involvement, and guide therapeutic decision-making.

The primary goals of AHF treatment are rapid stabilization of the patient, relief of congestion, correction of hypoxia, and management of the underlying cause. Initial therapy includes oxygen supplementation in hypoxemic patients, non-invasive ventilation for respiratory distress, and intravenous loop diuretics to reduce fluid overload. Intravenous vasodilators may be administered in patients with adequate blood pressure to decrease cardiac preload and afterload, whereas inotropes and vasopressors are reserved for patients with severe hypoperfusion or cardiogenic shock. Early identification and treatment of precipitating conditions, followed by optimization of guideline-

directed heart failure therapy before discharge, are essential to improve long-term clinical outcomes and reduce the risk of rehospitalization.

"Acute Heart Failure (AHF)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Heart Failure (AHF) pipeline landscape is provided which includes the disease overview and Acute Heart Failure (AHF) treatment guidelines. The assessment part of the report embraces, in depth Acute Heart Failure (AHF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Heart Failure (AHF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Heart Failure (AHF) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Heart Failure (AHF).

Acute Heart Failure (AHF) Emerging Drugs Chapters

This segment of the Acute Heart Failure (AHF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Heart Failure (AHF) Emerging Drugs

• IC14 (atibuclimab): Implicit Bioscience

IC14 (atibuclimab), developed by Implicit Bioscience, is a monoclonal antibody that targets CD14, a co-receptor involved in innate immune activation. By modulating CD14-mediated inflammatory signaling, it is designed to reduce excessive inflammation while preserving normal host defense. The drug is being developed for acute decompensated heart failure (ADHF). In January 2026, IC14 received FDA Fast Track designation for the treatment of hospitalized patients with ADHF, supporting its accelerated clinical development. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Acute Heart Failure (AHF).

Further product details are provided in the report……..

Acute Heart Failure (AHF): Therapeutic Assessment

This segment of the report provides insights about the different Acute Heart Failure (AHF) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Acute Heart Failure (AHF)

There are approx. 3+ key companies which are developing the therapies Acute Heart Failure (AHF). The companies which have their Acute Heart Failure (AHF) drug candidates in the most advanced stage, i.e. Phase I/II include, Implicit Bioscience, and others.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Acute Heart Failure (AHF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Heart Failure (AHF): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Heart Failure (AHF) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Heart Failure (AHF) drugs.

Acute Heart Failure (AHF) Report Insights

• Acute Heart Failure (AHF) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Heart Failure (AHF) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Heart Failure (AHF) drugs?
• How many Acute Heart Failure (AHF) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Heart Failure (AHF)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Heart Failure (AHF) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Heart Failure (AHF) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Implicit Biosciences
• AdrenoMed AG

Key Products

• IC14 (atibuclimab)
• Enibarcimab